CRNX Insider Trading

Insider Ownership Percentage: 6.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $17,839,827.22

Crinetics Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Crinetics Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

Crinetics Pharmaceuticals Share Price & Price History

Current Price: $29.11
Price Change: Price Increase of +2.26 (8.42%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for CRNX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$29.11Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Crinetics Pharmaceuticals (NASDAQ:CRNX)

98.51% of Crinetics Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CRNX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$423kbought$219ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More on Crinetics Pharmaceuticals

Today's Range

Now: $29.11
Low: $26.41
High: $29.26

50 Day Range

MA: $33.46
Low: $25.56
High: $39.30

52 Week Range

Now: $29.11
Low: $24.10
High: $62.53

Volume

1,379,285 shs

Average Volume

851,237 shs

Market Capitalization

$2.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Who are the company insiders with the largest holdings of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' top insider investors include:
  1. Richard Scott Struthers (CEO)
  2. Marc Wilson (CFO)
  3. Stephen F Betz (Insider)
  4. Jeff E Knight (COO)
  5. Dana Pizzuti (Insider)
  6. Alan Seth Krasner (Insider)
  7. James Hassard (Insider)
  8. Matthew K Fust (Director)
  9. Stephanie Okey (Director)
  10. Coelho Rogerio Vivaldi (Director)
Learn More about top insider investors at Crinetics Pharmaceuticals.

Who are the major institutional investors of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' top institutional investors include:
  1. Rhumbline Advisers — 0.14%
  2. Hennion & Walsh Asset Management Inc. — 0.04%
  3. GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of Crinetics Pharmaceuticals stock.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

During the previous quarter, CRNX stock was sold by these institutional investors:
  1. Hennion & Walsh Asset Management Inc.
During the last year, company insiders that have sold Crinetics Pharmaceuticals company stock include:
  1. Richard Scott Struthers (CEO)
  2. Marc Wilson (CFO)
  3. Stephen F Betz (Insider)
  4. Jeff E Knight (COO)
  5. Dana Pizzuti (Insider)
  6. Alan Seth Krasner (Insider)
Learn More investors selling Crinetics Pharmaceuticals stock.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

In the last quarter, CRNX stock was bought by institutional investors including:
  1. Rhumbline Advisers
  2. GAMMA Investing LLC